1 active not recruiting, 1 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Spinal Muscular Atrophy Type 3: new trials by email Literature Review of Spinal Muscular Atrophy Type 3 trials Research Report on Spinal Muscular Atrophy Type 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab Apitegromab - Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Phase 3 | Active not recruiting | Scholar Rock, Inc. | 238 | 2023-04-17 | 2026-09-01 |
| Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam Apitegromab, Placebo - Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Phase 3 | Completed | Scholar Rock, Inc. | 188 | 2022-04-14 | 2026-01-22 |
Atrophy (2) · Muscular Atrophy (2) · Muscular Atrophy, Spinal (2) · Neuromuscular Diseases (2) · Neuromuscular Manifestations (2) · Spinal Muscular Atrophies of Childhood (2)
Central Nervous System Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2) · Motor Neuron Disease (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Neurologic Manifestations (2) · Pathological Conditions, Anatomical (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Spinal Cord Diseases (2)
apitegromab (2)
Belgium (2) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Poland (2) · Spain (2) · United Kingdom (2) · United States (2)